Why Is There An Increased Risk Of Severe Adverse Perinatal Outcomes After The Use Of Clomiphene Citrate For Infertility Treatment?
Funder
National Health and Medical Research Council
Funding Amount
$570,065.00
Summary
Clomiphene citrate (CC) has been a first line treatment for female infertility internationally since the 1960’s. However, safety studies using routine prescribing practices were never performed, and numerous data sources now indicate that CC is associated with major adverse outcomes if the fetus is inadvertently exposed. We are linking prescription data to perinatal outcomes to confirm how CC is associated with adverse events so as to inform prescriber and practice change.
Cancer Epidemiology In High-risk Populations And Complex Cancers
Funder
National Health and Medical Research Council
Funding Amount
$451,716.00
Summary
My research program aims to better understand the causes of cancer and factors that influence outcomes after cancer diagnosis. It employs classical and innovative cancer epidemiology and includes large-scale studies of cancer incidence, survival and risk factors in people with immune dysfunction. It also includes studies of lymphoid malignancies and ‘cancer of unknown primary’ origin. The research program aims to build an evidence base for interventions that will reduce the burden of cancer nati ....My research program aims to better understand the causes of cancer and factors that influence outcomes after cancer diagnosis. It employs classical and innovative cancer epidemiology and includes large-scale studies of cancer incidence, survival and risk factors in people with immune dysfunction. It also includes studies of lymphoid malignancies and ‘cancer of unknown primary’ origin. The research program aims to build an evidence base for interventions that will reduce the burden of cancer nationally and internationally.Read moreRead less
Optimising Severe Malaria Treatment Using Pharmacokinetic-pharmacodynamic Modeling
Funder
National Health and Medical Research Council
Funding Amount
$218,490.00
Summary
Every year, severe malaria kills up to 800,000 people worldwide. To prevent death, a patient must be treated promptly and effectively. Children and adults vary in terms of their response to a malaria drug, and therefore may require a different dosing regimen. We will perform a rigorous analytical assessment of antimalarial drug concentration and efficacy data to determine dosing regimens. This will improve the treatment of severe malaria, and thereby, reduce malaria-related mortality.
Better Data To Inform Interventions To Reduce The Risk Of Stillbirth In Australia
Funder
National Health and Medical Research Council
Funding Amount
$75,830.00
Summary
Stillbirth is a devastating experience for parents and families. Paucity of high quality data on causes and contributing factors is a major barrier to the development of research priorities and interventions to prevent stillbirths and improve the quality of care. This research will be a connected body of work that aims to better describe the epidemiology of stillbirth in Australia, contribute to the classification of stillbirths and determine the needs of parents in relation to autopsy consent.
Temporal Trends In The Incidence, Site And Survival Of Metastatic Breast Cancer In Australia
Funder
National Health and Medical Research Council
Funding Amount
$190,494.00
Summary
There have been major advances in breast cancer treatment over the last decade. This project will use information collected from the NSW cancer registry and hospitals to report on changes in the type and risk of breast cancer spread and survival for women with a new diagnosis of breast cancer before and after new treatments introduced since 2005. This information is essential for doctors to provide women with up-to-date information; and for planning appropriate health services and research.
Hepatitis C Treatment-as-prevention In The Prison Setting
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
The burden of hepatitis C virus (HCV) infection in Australia is rising with prison settings being a major reservoir of HCV infection. This study evaluates the feasibility of a rapid scale-up of a new highly effective, short and tolerable HCV therapy and its impact on HCV transmission in the prison setting. This is the first HCV treatment-as-prevention study in prisons having strong potentials to inform public health policy nationally and internationally.